Shares of Beta Bionics, Inc. (NASDAQ: BBNX) surged 6.07% in after-hours trading on Tuesday following the company's release of impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.

The diabetes management solutions provider reported a 54% year-over-year increase in net sales, reaching $23.2 million for Q2 2025. This growth was driven by a 31% rise in the Durable Medical Equipment (DME) channel and a remarkable 498% surge in the Pharmacy Benefit Plan (PBP) channel. Beta Bionics also announced a significant increase in new patient starts, up 57% to 4,934 compared to the same period last year.

In light of these strong results, Beta Bionics raised its full-year 2025 revenue guidance to between $88 million and $93 million, up from the previous forecast of $82 million to $87 million. The company also improved its gross margin outlook for the year to 52%-55%. These positive developments, coupled with the expanding market penetration of its iLet Bionic Pancreas system, appear to have fueled investor optimism, resulting in the after-hours stock price surge.